Genmab A/S (GMAB.CO) Aktie Kurs
Genmab A/S Kurs
De seneste 19 år voksede Genmab A/Ss omsætning med 19,3 % årligt og nåede 592,57 Mio. USD. Indtjening pr. aktie er vokset med 17,7 % om året de seneste 12 år. For Genmab A/S er nettoavance på 25,9 % ned i forhold til 34,9 % for et par år siden. Konsensus 12-måneders kursmål for Genmab A/S er 343,66 USD, cirka under kursen med 39,1 %. Af 26 analytikere anbefaler 16 køb — den samlede vurdering er Køb.
Genmab A/S aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Genmab A/S aktie og aktieanalyse
Hyppigt stillede spørgsmål om Genmab A/S-aktien
The business model of Genmab A/S, a Danish biotechnology company, focuses on the development and commercialization of novel antibody therapeutics for the treatment of cancer. Genmab A/S specializes in the creation of differentiated and innovative antibody products, which are based on its proprietary antibody technologies. The company collaborates with various partners to advance its products through preclinical and clinical development stages. Genmab A/S aims to meet the needs of patients by discovering and delivering breakthrough treatments that target specific antigens involved in the progression of different types of cancer.
Genmab A/S is primarily active in the biotechnology industry.
The main competitors of Genmab A/S in the market include global pharmaceutical companies such as Roche Holding AG, Johnson & Johnson, Bristol-Myers Squibb Company, and Novartis AG. These companies are prominent players in the biopharmaceutical industry, engaging in research, development, and commercialization of innovative therapies. With its focus on the development of antibody-based drugs to treat cancer and other diseases, Genmab faces stiff competition in this highly regulated and competitive market. However, Genmab has established a strong reputation and is well-positioned with its innovative pipeline and strategic collaborations in the industry.
Genmab A/S is a Danish biotechnology company founded in 1999. The company specializes in the development of antibody therapeutics for the treatment of cancer and other diseases. Genmab has a strong focus on innovation and leveraging its proprietary antibody technologies to create novel drugs. Over the years, Genmab has established strategic collaborations with several pharmaceutical companies to advance its drug candidates. Notably, Genmab achieved significant success with the launch of Darzalex, an antibody-based therapy approved for multiple myeloma. The company continues to explore and develop groundbreaking therapies, harnessing the power of antibodies to improve patient outcomes and quality of life.
Genmab A/S, a leading biotechnology company, has achieved several significant milestones. One of the notable accomplishments is the development and approval of Darzalex (daratumumab), a breakthrough therapy for multiple myeloma. Genmab also entered into groundbreaking collaborations with renowned pharmaceutical companies, securing licensing agreements for their proprietary technology platforms. Additionally, the company has garnered worldwide recognition for its robust pipeline of innovative antibody-based therapies, addressing various unmet medical needs. Furthermore, Genmab's commitment to scientific excellence and steadfast dedication to improving patients' lives have earned them numerous prestigious awards and accolades within the biopharmaceutical industry.
Genmab A/S, a leading biotechnology company, is primarily present in various countries and regions. As a globally recognized player in the pharmaceutical industry, Genmab A/S has an extensive presence. The company operates in key markets such as the United States, Europe, Asia, and the Middle East. With a strong international footprint, Genmab A/S actively engages in research, development, and commercialization of innovative antibody-based therapies. Its continued growth and success are fueled by collaborations, partnerships, and a commitment to advancing breakthrough treatments for patients worldwide.
Genmab A/S represents values of innovation, dedication, and patient focus. The company believes in developing innovative antibody treatments to improve the lives of patients suffering from cancer and other diseases. Genmab prioritizes scientific excellence, collaboration, and striving for the best patient outcomes. Their corporate philosophy revolves around pushing boundaries, challenging the status quo, and making a meaningful impact in the field of biotechnology. Genmab A/S aims to deliver outstanding value for patients, healthcare providers, and shareholders through their commitment to research, development, and commercialization of novel antibody-based therapies.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 330,98 USD for Genmab A/S-aktien (median: 343,66 USD), svarende til -26,4 % i forhold til seneste kurs. Konsensus bygger på 26 analytikervurderinger.
27 analytikere vurderer i øjeblikket Genmab A/S-aktien: 17 anbefaler køb, 8 hold og 2 salg. For 2026 forventer analytikere, at Genmab A/S genererer omsætning på 4,47 Mrd. USD og indtjening pr. aktie på 11,00 USD.
Omregnet til den aktuelle valutakurs handles Genmab A/S-aktien til 505,94 EUR (564,71 USD).
Genmab A/S-aktien (GMAB.CO) er noteret på 8 børser, herunder: London (0MGB.L), Frankfurt (GE9.F), München (GE9.MU), Düsseldorf (GE9.DU), Wien (GMAB.VI), Kopenhagen (GMAB.CO).
Genmab A/S is an internationally leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer. The company, founded in 1999, is headquartered in Copenhagen, Denmark. Genmab also has offices in the United States, the Netherlands, Luxembourg, Japan, and China. Genmab operates its business in two main divisions: Research and Development, and Commercialization and Sales. Genmab's Research and Development department focuses on the discovery, development, and testing of antibodies for the treatment of cancer. The company is dedicated to developing innovative therapies for various types of cancer, including blood cancer, solid tumors, and hematological malignancies. Genmab's flagship product is Darzalex® (daratumumab), a monoclonal antibody for the treatment of patients with multiple myeloma. Darzalex® is now approved in the United States and distributed worldwide. Genmab also has a range of other antibodies in various stages of development, including tisotumab vedotin for the treatment of cervical cancer and advanced urothelial cancer, and enapotamab vedotin for the treatment of patients with solid tumors. The company works closely with other pharmaceutical and biotech companies to advance its research and development activities. Genmab has partnerships with companies such as Janssen Biotech, Novartis Pharmaceuticals, and Seattle Genetics to jointly develop and commercialize innovative therapies. Genmab's Commercialization and Sales department is responsible for the marketing and distribution of Darzalex® and other products. The company collaborates with other pharmaceutical companies, distribution partners, and regulatory authorities to ensure that the products are available, approved in the relevant markets, and accessible to patients. Genmab's business model is based on the development and commercialization of innovative and effective cancer therapies that meet the needs of patients. The company is committed to investing continuously in research and development and expanding its product pipeline to bring more therapies to the market in the future. Additionally, Genmab works closely with other companies to expand its reach and activities and further strengthen the company. In summary, Genmab A/S is an innovative biopharmaceutical company specializing in the development and commercialization of cancer therapies. The company has a wide range of products and a strong presence in the global market. With a strong research and development department and a dedicated sales department, Genmab aims to continue expanding and developing innovative therapies to meet the needs of patients.
forventet-omsætningen for Genmab A/S er 4,47 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Genmab A/S er 739,66 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Genmab A/S er i øjeblikket 51,35. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Genmab A/S-aktien.
Pris-til-salgs-forholdet (P/S) for Genmab A/S er i øjeblikket 8,50. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Genmab A/S-aktien.
AlleAktien-kvalitetsscore for Genmab A/S er 5/10.
ISIN for Genmab A/S er DK0010272202. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Genmab A/S er 565131. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Genmab A/S er GMAB.CO. Tickersymbolet bruges til at handle Genmab A/S-aktier på børsen.
Genmab A/S aktie
Genmab A/S Peer Group
Genmab A/S Ticker
Genmab A/S FIGI
Alle fundamentale data om Genmab A/S i deep dive
Vores aktieanalyse af Genmab A/S-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Genmab A/S. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: